September Drug Summary

In September, the FDA cleared Genentech’s Gavreto for patients with genetically altered lung cancer and approved Bristol Myers Squibb’s Onureg for acute myeloid leukemia. Qdolo permits greater tramadol dosing flexibility for pain, and new Trulicity doses may improve A1C and weight. Trelegy Ellipta is OK’d for asthma maintenance, and Xeljanz grabs its first pediatric indication. Nucala is the first biologic for hypereosinophilic syndrome, and Haegarda use for hereditary angioedema prevention is expanded for even younger patients.